| |
ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big NewsDec 6, 2023 |
|
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility. 
|
|
| By Nick Paul Taylor Merck KGaA just sent shockwaves through the BTK inhibitor space. Evobrutinib, the German drugmaker’s contender for a blockbuster opportunity, failed to beat Sanofi’s Aubagio in two phase 3 multiple sclerosis (MS) clinical trials, raising doubts about the prospects of a clutch of heavily backed rival candidates. |
|
|
|
By Max Bayer Johnson & Johnson's neuroscience pipeline is taking center stage, now one of three therapeutic focus areas mentioned in the company's business review. Three neuroscience drugs are expected to rake in $1-5 billion in revenue by 2030. |
By Max Bayer As a flurry of recent developments underscores the coming wave of new psychiatric treatments, one biotech is looking to carve out relevance in the PTSD space, pointing to new phase 2 data as evidence. |
Sponsored by Cell Signaling Technology CST fellow Amrik Singh outlines some of the key progress being made around CAR-T therapy and the impact that this highly specialized technique can have on cancer patients, even those who have been previously unresponsive to other forms of treatment. |
|
Learn about practical approaches to address instability and nonspecific binding challenges in this on-demand webinar from the ADME experts at BioIVT: Register Now >> 
|
|
By Annalee Armstrong Patients taking Pharvaris’ preventative oral medicine for hereditary angioedema had an 84.5% reduction in monthly attacks during a phase 2 study. The results represent a turnaround for the medicine, which until June was on a clinical hold by the FDA. |
Sponsored by IQVIA IQVIA’s new technologies are changing clinical trials, reducing the administrative burden on staff and improving insights for sponsors. |
By Nick Paul Taylor How much money does a biotech need to feel comfortable in today’s market? IGM Biosciences added to evidence that the number is big after the market closed Tuesday, when it revealed a 22% reduction in its headcount and prioritization of its pipeline to make the hundreds of millions in its bank go further. |
By Gabrielle Masson On the heels of a 35% workforce reduction and new CEO stepping in, Syros Pharmaceuticals is sharing an early snapshot of data from an AML trial that shows a 100% response rate among nine patients. |
By Max Bayer Coya and Dr. Reddy's are teaming up again on COYA 302, the former's ALS treatment nearing the clinic. The two were already collaborating on one of Dr. Reddy's biosimilars included as part of the asset's combo regimen. |
By Joseph Keenan Pfizer and Valneva have completed recruitment for a phase 3 trial of the Lyme disease vaccine VLA15 after work was halted earlier this year due to problems with one of the CROs at some of the trial sites. |
By Angus Liu Seagen unveiled detailed data showing its Tukysa could offer additional tumor progression benefit on top of Roche’s ADC Kadcyla. But with a negative early trend in overall survival, Seagen seems not ready to knock on the FDA’s door. |
By Dave Muoio Fitch Ratings' pessimistic 2024 outlook highlighted labor shortages, an uptick in union activity and potential second year of debt service covenant violations. |
By Andrea Park After wrapping up bankruptcy proceedings over the summer and, according to the company, emerging with all of its material customer contracts and tech development programs still in place, Rockley is ready to return to the process of finding buyers for its wrist-based biosensor. |
By Fraiser Kansteiner During an enterprise business review Tuesday, J&J laid out a range of expectations across the 2025 to 2030 timeframe. Chief among those, J&J says it will boast more than 10 drugs with peak sales potential of at least $5 billion, plus another 15-plus products with sales potential of at least $1 billion. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Whitepaper If you find yourself grappling with bioanalytical challenges during the drug development process, rest assured that these obstacles can be overcome - discover more! Sponsored by: Sannova Analytical |
Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| |
|
